A prospective observational pilot study of 38 adults without diabetes found that three months of semaglutide or tirzepatide treatment was associated with an average weight loss of 7.2 kg, reduced food cravings, increased satiety, and improved self-reported hunger control. Most participants reported smaller meal portions, while some experienced changes in food preferences, although the study could not establish whether the medications directly caused these behavioral changes.